Here are nine new drug shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists.
- Dextroamphetamine extended-release capsules: Teva has reported a shortage of dextroamphetamine sulfate extended-release capsules, a central nervous system stimulant used to treat ADHD and narcolepsy in 5-, 10- and 15-milligram presentations. No reason was provided for the shortage and Amneal’s Dexedrine Spansule capsules are available as alternatives.
- Ethionamide tablet: Pfizer has discontinued the manufacture of Trecator 250 milligram tablets, an anti-infective drug used in the treatment of tuberculosis. Supply is expected to last until September 2025.
- Insulin aspart injection: Novo Nordisk will discontinue unbranded insulin aspart injection products including FlexPen pens, PenFill cartridges and 10-milliliter vials by Dec. 31, 2025. Insulin aspart is a rapid-acting insulin used to control blood sugar in diabetes patients.
- Insulin aspart protamine and insulin aspart mix 70/30 injectable suspension: Novo Nordisk is discontinuing unbranded insulin aspart protamine and insulin aspart mix 70/30, a combination insulin product used for blood sugar control in diabetes by Dec. 31, 2025.
- Insulin degludec injection: Novo Nordisk plans to fully discontinue unbranded insulin degludec injections including U-100 and U-200 FlexTouch pens and 10-milliliter vials by Dec. 31, 2025. Insulin degludec is a long-acting basal insulin used for diabetes management.
- Lidocaine patch: Actavis Pharma has discontinued the NovaPlus label of the 5% lidocaine patch used for localized pain relief, including neuropathic pain and post-herpetic neuralgia.
- Oxaprozin tablet: Hospira has discontinued Daypro 600-milligram tablets, a nonsteroidal anti-inflammatory drug used to treat pain and inflammation associated with arthritis.
- Pemetrexed ditromethamine injection: Pfizer has discontinued the manufacture of pemetrexed ditromethamine injection in 100- and 500-milligram single-dose vials, an oncology drug used to treat various cancers, including non-small-cell lung cancer and mesothelioma.
- Potassium citrate tablet, extended release: Watson Pharma Private Limited has discontinued all extended-release potassium citrate tablets in 5-, 10- and 15-milliequivalent presentations, which are used to prevent kidney stones and treat some metabolic conditions. The discontinuation was due to a business decision.
